{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:05:00Z","timestamp":1790255100718,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006764","name":"TU Berlin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201292","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:10:45Z","timestamp":1784045445000},"page":"201292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Arming oncolytic Coxsackievirus B3 with Neoleukin-2\/15 enhances growth inhibition of colorectal carcinomas and induces T cell activation"],"prefix":"10.1016","volume":"34","author":[{"given":"Leslie","family":"Elsner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Girod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Hazini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne","family":"Heimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette","family":"Dieringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Shipman-Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-4002","authenticated-orcid":false,"given":"Andreas","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klopfleisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kurreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7581-7870","authenticated-orcid":false,"given":"Sophie","family":"Van Linthout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-4350","authenticated-orcid":false,"given":"Henry","family":"Fechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201292_bib1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201292_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/10430349950018832","article-title":"Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity","volume":"10","author":"Toda","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201292_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201292_bib4","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","article-title":"Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma","volume":"72","author":"Miyamoto","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201292_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2217\/fmb.15.5","article-title":"Coxsackievirus B3 replication and pathogenesis","volume":"10","author":"Garmaroudi","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.omton.2026.201292_bib6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3390\/v13050718","article-title":"Coxsackievirus B3-Its Potential as an Oncolytic Virus","volume":"13","author":"Geisler","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2026.201292_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bsheal.2023.09.001","article-title":"Update on enteroviral protease 2A: Structure, function, and host factor interaction","volume":"5","author":"Liu","year":"2023","journal-title":"Biosaf. Health"},{"key":"10.1016\/j.omton.2026.201292_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/rmv.1883","article-title":"Enteroviral proteases: structure, host interactions and pathogenicity","volume":"26","author":"Laitinen","year":"2016","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.omton.2026.201292_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1089\/hum.2018.036","article-title":"Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma","volume":"29","author":"Hazini","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201292_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011224","article-title":"Oncolytic Coxsackievirus B3 Strain PD-H Is Effective Against a Broad Spectrum of Pancreatic Cancer Cell Lines and Induces a Growth Delay in Pancreatic KPC Cell Tumors In Vivo","volume":"25","author":"Geisler","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201292_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215849","article-title":"A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice","volume":"548","author":"Bahreyni","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2026.201292_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12985-024-02502-y","article-title":"Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel","volume":"21","author":"Lin","year":"2024","journal-title":"Virol. J."},{"key":"10.1016\/j.omton.2026.201292_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0934-8840(11)80801-7","article-title":"Replication and persistence of coxsackieviruses B3 in human fibroblasts","volume":"282","author":"Tonew","year":"1995","journal-title":"Zentralbl. Bakteriol."},{"key":"10.1016\/j.omton.2026.201292_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/v13101918","article-title":"Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H","volume":"13","author":"Hazini","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2026.201292_bib15","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201292_bib16","doi-asserted-by":"crossref","first-page":"8464","DOI":"10.1073\/pnas.90.18.8464","article-title":"Characterization of cDNAs encoding the murine interleukin 2 receptor (IL-2R) gamma chain: chromosomal mapping and tissue specificity of IL-2R gamma chain expression","volume":"90","author":"Cao","year":"1993","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.omton.2026.201292_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201292_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201292_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cbpa.2020.02.002","article-title":"The advent of de novo proteins for cancer immunotherapy","volume":"56","author":"Quijano-Rubio","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.omton.2026.201292_bib20","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201292_bib21","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.omton.2026.201292_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of IL-2 and IL-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201292_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","article-title":"Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation","volume":"10","author":"Luo","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201292_bib24","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.virs.2024.09.007","article-title":"A novel vesicular stomatitis virus armed with IL-2 mimic for oncolytic therapy","volume":"39","author":"Wu","year":"2024","journal-title":"Virol. Sin."},{"key":"10.1016\/j.omton.2026.201292_bib25","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/pro.5560051107","article-title":"Cleavage site analysis in picornaviral polyproteins: discovering cellular targets by neural networks","volume":"5","author":"Blom","year":"1996","journal-title":"Protein Sci."},{"key":"10.1016\/j.omton.2026.201292_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083753","article-title":"An attenuated coxsackievirus b3 vector: a potential tool for viral tracking study and gene delivery","volume":"8","author":"Zeng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201292_bib27","doi-asserted-by":"crossref","first-page":"7952","DOI":"10.1128\/JVI.74.17.7952-7962.2000","article-title":"Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice","volume":"74","author":"Chapman","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201292_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/hum.2020.228","article-title":"miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas","volume":"32","author":"Hazini","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201292_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omto.2022.10.003","article-title":"Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3","volume":"27","author":"Liu","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201292_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011642","article-title":"Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors","volume":"13","author":"Jiang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201292_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12985-022-01795-1","article-title":"A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 \u00d7 CCL19 results in enhanced antitumor efficacy","volume":"19","author":"Hu","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.omton.2026.201292_bib32","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1128\/JVI.74.10.4570-4578.2000","article-title":"Expression of an antigenic adenovirus epitope in a group B coxsackievirus","volume":"74","author":"H\u00f6fling","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201292_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00309-23","article-title":"Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome","volume":"97","author":"Sam","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201292_bib34","doi-asserted-by":"crossref","first-page":"8124","DOI":"10.1128\/jvi.70.11.8124-8127.1996","article-title":"Foot-and-mouth disease virus 2A protease mediates cleavage in attenuated Sabin 3 poliovirus vectors engineered for delivery of foreign antigens","volume":"70","author":"Mattion","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201292_bib35","doi-asserted-by":"crossref","first-page":"8187","DOI":"10.1128\/JVI.75.17.8187-8194.2001","article-title":"Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis","volume":"75","author":"Henke","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201292_bib36","doi-asserted-by":"crossref","first-page":"12759","DOI":"10.1128\/JVI.00661-11","article-title":"A novel pancreatropic coxsackievirus vector expressing glucagon-like peptide 1 reduces hyperglycemia in streptozotocin-treated mice","volume":"85","author":"Dan","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201292_bib37","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1128\/JVI.75.5.2377-2387.2001","article-title":"Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection","volume":"75","author":"Slifka","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201292_bib38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000321351","article-title":"Destabilization of coxsackievirus b3 genome integrated with enhanced green fluorescent protein gene","volume":"54","author":"Tong","year":"2011","journal-title":"Intervirology"},{"key":"10.1016\/j.omton.2026.201292_bib39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.yjmcc.2005.02.018","article-title":"Long-term cardiac gene expression using a coxsackieviral vector","volume":"38","author":"Lim","year":"2005","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.omton.2026.201292_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1128\/JVI.72.1.20-31.1998","article-title":"Expression of foreign proteins by poliovirus polyprotein fusion: analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames","volume":"72","author":"Mueller","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201292_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001292","article-title":"Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy","volume":"9","author":"Khalique","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201292_bib42","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-19-0628","article-title":"Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade","volume":"8","author":"Lin","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201292_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/mt.2013.238","article-title":"Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201292_bib44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00262-004-0627-4","article-title":"Local interleukin 2 therapy is most effective against cancer when injected intratumourally","volume":"54","author":"Jacobs","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201292_bib45","first-page":"262","article-title":"A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2","volume":"100","author":"Rosenberg","year":"1986","journal-title":"Surgery"},{"key":"10.1016\/j.omton.2026.201292_bib46","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201292_bib47","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.omton.2026.201292_bib48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201292_bib49","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/cvr\/cvz259","article-title":"Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas","volume":"116","author":"Pinkert","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.omton.2026.201292_bib50","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1128\/jvi.70.11.7632-7640.1996","article-title":"Mutagenesis of the coxsackie B3 virus 2B\/2C cleavage site: determinants of processing efficiency and effects on viral replication","volume":"70","author":"van Kuppeveld","year":"1996","journal-title":"J. Virol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:34:54Z","timestamp":1790253294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001682"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201292","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arming oncolytic Coxsackievirus B3 with Neoleukin-2\/15 enhances growth inhibition of colorectal carcinomas and induces T cell activation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201292"}}